

Delphine Planas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3597485/publications.pdf>

Version: 2024-02-01

42
papers

6,570
citations

279798

23
h-index

276875

41
g-index

64
all docs

64
docs citations

64
times ranked

10557
citing authors

#	ARTICLE	IF	CITATIONS
1	Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. <i>Nature</i> , 2021, 596, 276-280.	27.8	1,803
2	Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. <i>Nature</i> , 2022, 602, 671-675.	27.8	1,202
3	Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. <i>Nature Medicine</i> , 2021, 27, 917-924.	30.7	617
4	Syncytia formation by SARS-CoV-2 in infected cells. <i>EMBO Journal</i> , 2020, 39, e106267.	7.8	361
5	Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. <i>Nature Medicine</i> , 2022, 28, 1297-1302.	30.7	235
6	A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	228
7	Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. <i>EBioMedicine</i> , 2021, 71, 103561.	6.1	172
8	Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. <i>Nature Communications</i> , 2021, 12, 844.	12.8	146
9	SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced Spike-mediated syncytia formation. <i>EMBO Journal</i> , 2021, 40, e108944.	7.8	139
10	HIV persists in CCR6+CD4+ T cells from colon and blood during antiretroviral therapy. <i>Aids</i> , 2017, 31, 35-48.	2.2	122
11	Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. <i>Nature</i> , 0, , .	27.8	88
12	HIV-1 selectively targets gut-homing CCR6+CD4+ T cells via mTOR-dependent mechanisms. <i>JCI Insight</i> , 2017, 2, .	5.0	75
13	Identification of novel HIV-1 dependency factors in primary CCR4+CCR6+Th17 cells via a genome-wide transcriptional approach. <i>Retrovirology</i> , 2015, 12, 102.	2.0	54
14	LILAC pilot study: Effects of metformin on mTOR activation and HIV reservoir persistence during antiretroviral therapy. <i>EBioMedicine</i> , 2021, 65, 103270.	6.1	46
15	A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients. <i>Kidney International</i> , 2022, 101, 1073-1076.	5.2	44
16	Effect of metformin on the size of the HIV reservoir in non-diabetic ART-treated individuals: single-arm non-randomised Lilac pilot study protocol. <i>BMJ Open</i> , 2019, 9, e028444.	1.9	39
17	Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 720-728.	0.9	39
18	Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 73, e1337-e1344.	5.8	35

#	ARTICLE	IF	CITATIONS
19	Potent human broadly SARS-CoV-2 neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	34
20	Repurposing Metformin in Nondiabetic People With HIV: Influence on Weight and Gut Microbiota. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa338.	0.9	33
21	Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and Serological Estimation of Time Since Infection. <i>Journal of Infectious Diseases</i> , 2021, 224, 1489-1499.	4.0	32
22	New Th17-specific therapeutic strategies for HIV remission. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 85-92.	3.8	30
23	HIV-1 is rarely detected in blood and colon myeloid cells during viral-suppressive antiretroviral therapy. <i>Aids</i> , 2019, 33, 1293-1306.	2.2	28
24	Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2120976119.	7.1	27
25	Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma. <i>Blood</i> , 2022, 139, 942-946.	1.4	24
26	Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques. <i>Nature Communications</i> , 2021, 12, 5215.	12.8	22
27	Digoxin reveals a functional connection between HIV-1 integration preference and T-cell activation. <i>PLoS Pathogens</i> , 2017, 13, e1006460.	4.7	21
28	Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective study. <i>EBioMedicine</i> , 2021, 73, 103637.	6.1	19
29	Th17 cell master transcription factor RORC2 regulates HIV-1 gene expression and viral outgrowth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	17
30	COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1357-1365.	0.7	17
31	Improving HIV Outgrowth by Optimizing Cell-Culture Conditions and Supplementing With all-trans Retinoic Acid. <i>Frontiers in Microbiology</i> , 2020, 11, 902.	3.5	15
32	Daily variations of gut microbial translocation markers in ART-treated HIV-infected people. <i>AIDS Research and Therapy</i> , 2020, 17, 15.	1.7	14
33	Severe relapse of SARS-CoV-2 infection in a kidney transplant recipient with negative nasopharyngeal SARS-CoV-2 RT-PCR after rituximab. <i>American Journal of Transplantation</i> , 2022, 22, 2099-2103.	4.7	14
34	Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination. <i>Viruses</i> , 2022, 14, 1491.	3.3	13
35	Pharmacological Inhibition of PPAR γ Boosts HIV Reactivation and Th17 Effector Functions, while Preventing Progeny Virion Release and <i>de novo</i> Infection. <i>Pathogens and Immunity</i> , 2020, 5, 177.	3.1	12
36	Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2. <i>EBioMedicine</i> , 2022, 77, 103934.	6.1	10

#	ARTICLE	IF	CITATIONS
37	Species-Specific Molecular Barriers to SARS-CoV-2 Replication in Bat Cells. <i>Journal of Virology</i> , 2022, 96, .	3.4	10
38	Diurnal Variation of Plasma Extracellular Vesicle Is Disrupted in People Living with HIV. <i>Pathogens</i> , 2021, 10, 518.	2.8	5
39	Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine. <i>Frontiers in Immunology</i> , 2022, 13, 790212.	4.8	3
40	Transmission of SARS-CoV-2 Alpha Variant (B.1.1.7) From a BNT162b2-Vaccinated Individual. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab369.	0.9	2
41	Persistence of Sera Neutralizing Activity Six Month after Hospitalization for COVID-19. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
42	Flow Cytometry Sorting of Memory CCR6+CD4+ T-Cells for HIV Reservoir Quantification. <i>Methods in Molecular Biology</i> , 2022, 2407, 81-89.	0.9	0